Indications And Dose
Variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer) ▶Adult: (consult product literature)
PDF page 1002
Loading InternPractice…
Drug reference
Variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer) ▶Adult: (consult product literature)
PDF page 1002
Intrathecal injection contra- indicated.
PDF page 1002
Caution in handling—irritant to tissues. neuromuscular disease
PDF page 1002
Vindesine injections are for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal. The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.
PDF page 1002
→Appendix 1: vinca alkaloids
PDF page 1002
▶Common or very common Alopecia ▶Frequency not known Anaemia. appetite decreased. asthenia. balance impaired. cellulitis. chills. constipation . depression. diarrhoea. dizziness. dysphagia. fever. gastrointestinal discomfort. gastrointestinal disorders. granulocytopenia (dose-limiting). headache. hearing impairment. malaise. nausea. nerve disorders. nystagmus . oral disorders. pain. peroneal nerve palsy. rash maculopapular. reflexes absent. seizure. sensation abnormal. thrombocytopenia. thrombocytosis. vertigo. vestibular damage. vision loss. vomiting SIDE-EFFECTS, FURTHER INFORMATION Neurotoxicity, usually as peripheral or autonomic neuropathy; it occurs less often with vindesine than with vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes; and ototoxicity has been reported. There have been instances in which neurotoxicity has made it necessary to reduce the dosage or temporarily discontinue use of vindesine.
PDF pages 1002, 1003
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1003
Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1003
Discontinue breast-feeding.
PDF page 1003
Manufacturer advises caution. Dose adjustments Manufacturer advises consider initial dose reduction in significant impairment.
PDF page 1003
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for injection ▶Eldisine (Genus Pharmaceuticals Ltd) Vindesine sulfate 5 mg Eldisine 5mg powder for solution for injection vials | 1 vial P £78.30 (Hospital only)
PDF page 1003
(consult product literature)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1002